The ganglioside GM3(Neu5Gc) has gained increasing attention as therapeutic target because of its selective expression in various human tumours, such as melanoma, breast and lung cancer. 14F7 is a mouse IgG1 with specific reactivity to GM3(Neu5Gc)-positive tumours. The therapeutic activity of 14F7 has also been demonstrated in vivo, through its repetitive passive administration in tumour-bearing animals. In this work we used an alternative strategy to deliver recombinant 14F7 in vivo and analysed the therapeutic efficacy of this approach. We engineered a recombinant adeno-associated vector to direct the expression of secretable recombinant 14F7 in BALB/c animals. A single administration of the rAAV induced efficient production and secretion of the antibody in the bloodstream, with an expression level reaching plateau at ∼ 3 weeks after injection and persisting for almost a year. Strikingly, upon challenge with GM3(Neu5Gc)-positive X63-AG8.653 myeloma cells, tumour development was significantly delayed in animals treated with rAAV-14F7 with respect to animals treated with a control rAAV codifying for an irrelevant antibody. Finally, no significant differences in survival proportion were detected in animals injected with rAAV-14F7 or treated by standard administration of repetitive doses of purified monoclonal antibody 14F7.
INTRODUCTION
Gangliosides are sialic acid-containing glycosphingolipids that are essential constituents of the outer layer of vertebrates' plasma membrane, where they work as modulators of signal transduction and mediators of cell-cell recognition and communication. 1, 2 Besides being involved in fundamental physiological processes like growth, differentiation and apoptosis, the relevant role played by gangliosides in tumour progression and tumour-induced immunosuppression has also been recently highlighted. [3] [4] [5] [6] Overexpression or altered glycosylation of gangliosides are characteristic traits of numerous tumours, particularly malignant melanoma and tumours of neuroectodermic origin. [7] [8] [9] [10] The expression of N-glycolylated gangliosides is a rare event in human normal cells because of the inactivation of the enzyme responsible for N-glycolyl-sialic acid (Neu5Gc) biosynthesis in humans. 11 Conversely, the presence of N-glycolylated gangliosides has been reported in human tumours, [12] [13] [14] probably as the result of diet incorporation, [15] [16] [17] together with hypoxia-induced increased sialic acid entry to cells from the external milieu. 18, 19 Because of its selective expression on tumour cells, GM3(Neu5Gc) in particular represents a promising target for immunotherapeutic approaches, 20 such as vaccination or passive administration of monoclonal antibodies (mAbs). 14F7 is a mouse IgG1 mAb highly specific to GM3(Neu5Gc), generated by immunising BALB/c animals with the ganglioside conjugated to human very-lowdensity lipoproteins in the presence of Freund's adjuvant. 21 The reactivity of 14F7 to frozen, formalin-fixed or paraffinembedded tumour samples of different origin, such as breast tumours, melanoma, epithelial-derived tumours and haematological malignancies, has been reported. [21] [22] [23] [24] [25] Interestingly, when passively administered in vivo, mouse mAb 14F7 exhibited therapeutic activity in GM3(Neu5Gc)-positive tumour-bearing mice. 26 The capacity of 14F7 to induce GM3(Neu5Gc)-positive tumour cell death has possibly to be ascribed to its direct cytotoxic effect 26, 27 rather than to complement-dependent cytotoxicity or to antibody-dependent cell cytotoxicity. 26 This direct cytotoxic effect of 14F7 mAb (for example, complement-and effector cell-independent) is not completely understood yet. 28 It does not display features of apoptotic cell death, as caspase activation and DNA fragmentation, 27 but instead involves cytoskeleton proteins and causes large membrane lesions in target cells. Moreover, not only the presence of the ganglioside, but also its distribution into lipid rafts is important for the cytotoxic activity of the antibody. 27 In the present work we further exploit the biological activity of 14F7 in vivo in a new therapeutic setting. We developed a genetic strategy to induce the in vivo long-term expression of mAb 14F7 using a recombinant adenoassociated virus (rAAV) vector. AAVs are small (20-25 nm), non-enveloped, linear single-stranded DNA Parvoviruses, with the capacity to infect humans and other animal species. The rAAV vectors have been extensively characterised and studied for gene therapy purposes because of their exclusive capacity of inducing transgene long-term expression in vivo, in both dividing and non-dividing cells, and in the absence of any viral-associated pathogenicity. 29 Although integration into genomic DNA can occur in some cases, long-term expression is achieved mainly through episomal maintenance of the rAAV DNA that, upon infection, is converted into double-stranded DNA, concatemerised and circularised. [30] [31] [32] Numerous clinical trials based on rAAV have been successfully conducted or are currently in progress in the treatment of inherited or acquired diseases, such as haemophilia B, 33 cystic fibrosis, 34 rheumatoid arthritis 35 and macular degeneration, 36 suggesting a continuous interest in this vector in the field of gene therapy. The in vivo expression of recombinant antibodies by rAAV-mediated gene transfer in several disease models has also been reported. [37] [38] [39] [40] [41] [42] [43] In this work we report the induction of long-term expression (almost 10 months) of the 14F7 antibody in blood circulation of animals injected with a recombinant AAV2/9-derived vector codifying for the light and heavy chains of mAb 14F7 (rAAV--14F7). Moreover, we demonstrate that the in vivo expression of recombinant 14F7 is associated with a widespread immunoprotection that prevented tumour development upon injection of GM3(Neu5Gc)-positive myeloma cells. Strikingly, tumour protection induced by rAAV was comparable to the one generated by repetitive administration of purified mAb 14F7, thus providing proof of concept for further exploiting this approach as first-line or maintenance therapy in clinical cancer management.
RESULTS

The rAAV vectors and antibody expression
We engineered two different rAAV vectors, namely rAAV-14F7 and rAAV-ctrl, encoding, respectively, the light and heavy chains of mAb 14F7 or of an irrelevant IgG (Figure 1a ). To guarantee equimolar expression of the immunoglobulin light and heavy chains we used a bicistronic expression system based on peptide 2A from the foot-and-mouth disease virus. 40, 44 Because of its co-translational self-processing activity, 2A allows expression of two different proteins from the same mRNA rather efficiently. Peptide 2A was cloned between the two immunoglobulin chains. A four-amino-acid sequence cleavage site for furin was also introduced upstream of 2A to direct its proteolytic cleavage from the C-terminus of the immunoglobulin light chain upon trafficking through the Golgi (Figure 1a ). Expression of the transgene cassette was tested in cultured cells by transient transfection of HEK-293T cells and western blot on cell supernatants. Both antibodies were found to be actively secreted as polypeptides of ∼ 150 kDa (Figure 1b , polyacrylamide gel electrophoresis in nonreducing conditions), suggesting that the processing and assembling of the two antibodies occur correctly in living cells. The level of expression of the recombinant 14F7 and the control antibody were comparable. Analysis of 14F7 expression in reducing conditions showed the light chain present in cellular extracts to be still fused to 2A, as expected for molecules that have not yet trafficked through the Golgi and processed by furin, whereas in the culture supernatants the secreted light chain was in part not fully processed, probably because of the large amounts produced. Binding capacity of the recombinant 14F7-IgG to GM3(Neu5Gc) antigen was tested by incubating supernatants from transfected HEK-293T cells with a panel of GM3(Neu5Gc)-positive and control cell lines ( Figure 1c ). Specifically, we tested two GM3(Neu5Gc)positive cell lines, namely X63-AG8.653 mouse myeloma cells and L1210 mouse lymphocytic leukemia cells. Flow cytometry analysis revealed specific binding of the recombinant 14F7 on these cell lines with respect to the negative IgG control. Binding activity was comparable to the original mAb 14F7. To confirm the selective specificity of our recombinant 14F7 antibody to the glycolylated form of the GM3 ganglioside, we incubated the supernatant of transfected cells with a variant of the L1210 cell line, namely L1210 cmah-kd. This cell line was obtained by silencing the cmah gene encoding for the enzyme cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMP-Neu5Ac hydroxylase) responsible for the conversion of Neu5Ac to Neu5Gc. 45 As expected, the silencing of this gene resulted in complete suppression of binding by both the recombinant and the original mAb 14F7. No binding activity was detected either on GM3(Neu5Gc)-negative CT-26 mouse colon carcinoma cells.
The in vivo antibody expression and functional analysis To address the capacity of rAAV vectors to direct in vivo expression of the recombinant 14F7, mice were injected intramuscularly (i.m.) in the leg femoral muscle. The level of circulating recombinant 14F7-IgG in peripheral blood was measured by enzyme-linked immunosorbent assay (ELISA) on GM3(Neu5Gc)-coated plates 1 week after i.m. injection of two different doses of rAAV, namely 1 × 10 11 or 3 × 10 12 viral genome particles (v.p.). The recombinant 14F7 antibody was detectable in blood circulation at both doses ( Figure 2a ). Yet, injection with the highest dose of rAAV-14F7 produced a higher concentration of circulating recombinant 14F7 IgG in peripheral blood.
To assess the efficacy of in vivo processing of recombinant 14F7 expressed from transduced cells, sera from injected animals were adsorbed on GM3(Neu5Gc)-coated plates and bound material was analysed in western blot after SDS elution from the plates. Under nonreducing conditions, a single band was detected corresponding to the complete and correctly assembled antibody. The two bands detected in reducing conditions indicate that the 2A peptide is efficiently processed in vivo through the enzymatic cleavage of furin ( Figure 2b ). These results indicate that a single injection of rAAV is sufficient to allow accumulation of recombinant 14F7 in peripheral blood as early as 1 week after injection. The antibody had antigen-binding properties, as it recognised purified GM3(Neu5Gc). These data were confirmed with an SV5-tagged version of the antibody (Supplementary Figure S1 ). As the biological effect of the recombinant antibody in vivo should directly depend on its blood concentration, we decided to perform all further experiments with the dose of 3 × 10 12 v.p.
To determine whether the route of rAAV administration had any effect on the expression level of recombinant 14F7 in vivo, mice were injected i.m. or intravenously (i.v.) with a single dose of 3 × 10 12 rAAV-14F7. The reactivity of recombinant 14F7 in serum was then measured by ELISA on GM3(Neu5Gc)-coated plates ( Figure 3a ). The results indicated that i.m. injection favours antibody accumulation in the peripheral blood with respect to i.v. administration.
The capacity of rAAV to induce persistent expression of recombinant 14F7 in vivo was evaluated in ELISA by measuring antibody titres in the sera of injected animals at different time points ( Figure 3b ). Serum levels of 14F7 progressively increased with time, reaching a plateau at ∼ 3 weeks after injection and were thereafter sustained for almost 1 year. The absolute highest concentration of antibody reached at week 3 was estimated at ∼ 70 μg ml − 1 (Figure 3c ).
The recombinant antibody secreted in the blood circulation was demonstrated to also retain antigen-binding activity on target GM3(Neu5Gc)-positive X63-AG8.653 myeloma cells. Binding was tested by flow cytometry upon incubation of target cells with rAAV-14F7 or rAAV-ctrl sera (Figure 3d ). Our results showed that rAAV-mediated expression allows for the in vivo production of a fully competent recombinant 14F7 that is able to recognise its cognate antigen.
Previous studies have demonstrated the ability of mAb 14F7 to induce target cell death through a direct cytotoxic effect. 26, 27 To address the biological activity of recombinant 14F7 in our model, GM3(Neu5Gc)-positive X63-AG8.653 myeloma cells were cultured with sera from animals injected with rAAV-14F7 or rAAV-ctrl. The percentage of dead cells was measured by standard staining with propidium iodide. Sera from animals injected with rAAV-14F7 significantly affected cell viability, with a percentage of dead cells of ∼ 69% compared with 93% of the positive control with purified 14F7 and 27% of rAAV-ctrl serum (Figure 4a ).
Anti-idiotype immune response
The induction of anti-idiotypic antibodies against 14F7 could have a negative impact on the clinical outcome of our approach and ultimately affect the long-term expression of the antibody.
To exclude this possibility, sera from animals injected with rAAV-14F7 were taken 3 weeks post injection and tested for the presence of anti-idiotypic antibodies by ELISA. Plates were coated with a mouse/human chimeric version of 14F7 to specifically detect serum antibodies against 14F7 variable regions. Compared with a positive anti-14F7 idiotype control serum induced by gene gun immunisation with a scFv-mouse CH3 construct (unpublished data), no response was detected in the sera from rAAV-14F7injected animals (Figure 4b ).
Tumour protection
We then investigated the efficiency of rAAV-mediated antibody delivery in promoting tumour rejection. To address this point, mice were injected with 3 × 10 12 v.p. of rAAV-14F7 or rAAV-ctrl. After 1 month, animals were challenged with 2 × 10 5 X63-AG8.653 myeloma cells and followed-up for survival ( Figure 5a ). Injection with rAAV-14F7 significantly delayed tumour onset compared with rAAV-ctrl and some animals were completely protected from tumour challenge.
Additional survival experiments were performed in order to compare tumour protection upon a single i.m. injection of rAAV-14F7 or repetitive i.v. administration of purified 14F7 (Figure 5b ). The latter approach has been already demonstrated to exert antitumour effect when implemented immediately after tumour challenge. 26 For this set of experiments, a group of animals were injected with rAAV-14F7 and challenged with myeloma cells as described above. Survival of these animals was compared with the one obtained in a second group of animals treated by repetitive injection of 300 μg per dose of purified 14F7 performed at days 2, 3, 4 and 5 after tumour challenge. Tumourfree survival proportions were comparable in these two groups, yet revealing that a single injection of rAAV-14F7 is an efficient strategy to induce not only long-term expression of mAb 14F7 rAAV-mediated targeting of ganglioside GM3(Neu5Gc) but, most notably, systemic immunoprotection against tumour development.
DISCUSSION
The mAbs represent one of the leading technologies in the cancer immunotherapy arena. As of late 2013, there were ∼ 13 mAbs approved by the Food and Drug Administration (FDA) for the treatment of cancer in the US market, and new candidates are continuously entering into clinical trials. 46 The development and production of mAbs is a rather long and cost-demanding process. Furthermore, to achieve a therapeutic level of mAb in blood circulation, repetitive administrations are needed, and hence treatment with mAbs becomes a rather invasive procedure for patients. Because of all these obstacles, increasing attention is being paid to the development of alternative strategies to induce the systemic long-term expression of therapeutic antibodies in vivo. In this work we have exploited in vivo gene transfer via injection of a rAAV to establish the production of therapeutic levels of anti-GM3(Neu5Gc) mAb 14F7. Strikingly, upon tumour challenge the overall survival of the animals treated with a rAAV encoding antibody 14F7 was comparable to that obtained in previous works by standard repetitive injections of high dose of purified mAb 14F7. 26 To induce expression of therapeutic levels of recombinant 14F7 we generated a bicistronic vector based on viral peptide 2A. Transfection of cultured cells with plasmid pAAV-14F7 gave rise to the production of a fully functional antibody, capable of recognising the cognate antigen as a purified molecule as well as in its native state on the surface of target tumour cells. Antibody processing and expression were found to be just as effective in vivo, as functional recombinant antibody 14F7 was detected in animal circulation just a week after rAAV injection. This is in line with previous works reporting the in vivo expression of recombinant antibodies by rAAV-mediated gene transfer in several preclinical models of viral and parasitic diseases, 37-39 cancer 40, 43 and neurological conditions. 41, 42 Our recombinant vector refers to AAV serotype 9. AAV-9 has been reported to infect mainly muscle tissue when injected locally, whereas i.v. injection seems to determine preferentially infection of the liver, followed by heart and smooth muscle. 47 In our model, we have experienced higher levels of circulating 14F7 antibody when the virus was administered by i.m. injection compared with i.v. injection. Following i.m. administration, the level of circulating antibodies increased progressively with time, to reach a plateau at ∼ 3 weeks after rAAV injection when the concentration of recombinant 14F7 was ∼ 70 μg ml − 1 . It is interesting to notice that the antibody was still detectable in the bloodstream 10 months after rAAV injection. Administration of rAAV-9 was shown not to be associated with induction of anti-AAV antibodies. 47 We reason that the absence of an anti-AAV humoural response may somehow contribute to the long-term expression of the transgene in our system, even though the levels of the anti-AAV antibodies in the circulation of rAAV-14F7-treated animals were not measured. The induction of anti-AAV antibodies is not the only event that could adversely affect the success of our approach. One possible additional complication associated with the administration of therapeutic antibodies in immunocompetent individuals is the induction of an anti-idiotypic immune response. In our system the expression of the recombinant 14F7 was not associated with the induction of anti-idiotypic antibodies, (b) Three groups of animals (n = 6 per group) were treated as described in (a) and challenged by s.c. injection of 2 × 10 5 X63-AG8.653 tumour cells. In an additional group, animals were similarly injected s.c. with 2 × 10 5 X63-AG8.653 myeloma cells and then treated by i.v. administration of 300 μg per dose of purified mAb 14F7 at days 2, 3, 4 and 5 after tumour cell injection. Animals were followed-up until moribund and then killed. Survival analysis was performed using the Kaplan-Meier product-limit method.
The log-rank test was used to compare survival curves. ***P o0.001.
rAAV-mediated targeting of ganglioside GM3(Neu5Gc) at least after 3 weeks of rAAV injection. This is in line with previous work that reported induction of anti-idiotypic antibodies to mAb 14F7 only when the antibody was coupled to a carrier protein and administered in combination with Freund's adjuvant, whereas with the antibody in adjuvant alone no response was detected. 48 No evident side effects of our approach associated with 14F7mediated targeting of normal tissues expressing GM3(Neu5Gc) or with off-targeting were observed. However, this eventuality cannot be completely ruled out when transferring this strategy to the human setting. The therapeutic activity of mAb 14F7 was previously demonstrated in BALB/c animals challenged with X63-AG8.653 myeloma cells and subsequently treated with repeated administration of up to 200 μg per dose. 26 The treatment resulted in ∼ 70% of survival 2 weeks after tumour challenge. In our setting, at this time point tumour growth was prevented in the totality of the animals, suggesting that the therapeutic efficacy of the two approaches is similar. When we ran a side-by-side comparison of survival of animals treated with rAAV-14F7 or injected with purified 14F7, survival rate proportions were not significantly different. This result demonstrates that a gene-therapy approach based on a single injection of a rAAV encoding a therapeutic antibody could effectively replace the complex clinical standard procedure of repetitive injections of high quantity of purified antibody, at least in the case of GM3(Neu5Gc) targeting. This result is even more remarkable in light of the growing importance of gangliosides, and in particular of GM3(Neu5Gc), as tumour targets. GM3 (Neu5Gc) is overexpressed in a wide variety of human tumours and its role in tumour development and its interaction with tumour microenvironment has now begun to be clarified. 49 Similar to N-acetyl-GM3 (GM3(Neu5Ac)), 5 GM3(Neu5Gc) has been demonstrated to act as immunosuppressor inhibiting CD4 T cells and dendritic cell functionality. 3, 6, 50 In a mouse model of GM3 (Neu5Gc)-expressing lymphocytic leukemia, in vivo tumour growth was significantly impaired by selective inhibition of the enzyme responsible for the conversion of Neu5Ac to Neu5Gc. 45 When considering possible therapies involving the use of antibodies against GM3(Neu5Gc) in cancer therapy, recent evidences have to be taken into account suggesting a possible involvement of low doses of anti-Neu5Gc antibodies in promoting tumour growth in a Neu5Gc-deficient (Cmah − / − ) mouse model. 51, 52 In this context, anti-Neu5Gc antibodies seem to contribute to the establishment of an inflammatory reaction as a result of diet incorporation of Neu5Gc into tissues. However, a direct correlation between dietary-Neu5Gc incorporation, generation of anti-Neu5Gc antibodies and an increased risk of chronic inflammation or cancer has not been formally demonstrated in humans. Moreover, further studies demonstrated that in the same Neu5Gc-deficient (Cmah − / − ) mouse model the administration of high doses of anti-Neu5Gc antibodies induces tumour regression. 52 Finally, clinical trials involving the use of a GM3(Neu5Gc)-based vaccine 53, 54 or an antiidiotypic vaccine 55, 56 in which humoural anti-GM3(Neu5Gc) response was generated demonstrated safety of the treatment and, in some cases, clinical efficacy, a further confirmation of the potential of GM3(Neu5Gc) as a target in cancer therapy. It goes without saying that development of alternative strategies for in vivo GM3(Neu5Gc) targeting will eventually contribute to the design of more effective cancer therapies. The approach of genetic immunisation via injection of rAAV codifying for a therapeutic antibody proposed in this work perfectly lies within this scope.
MATERIALS AND METHODS
Cell lines and animals
HEK 293T cells were grown in Dulbecco's modified Eagle's medium (Life Technologies, Waltham, MA, USA) supplemented with 10% fetal calf serum (Life Technologies) at standard conditions: 37°C, 5% CO 2 and humidified atmosphere. X63-AG8.653 mouse myeloma cell line and CT-26 mouse colon carcinoma cell line were maintained in culture in RPMI-1640 (Life Technologies) supplemented with 10% fetal calf serum at standard conditions. L1210 mouse lymphocytic leukemia cell line and L1210 cmahkd cells 45 were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum at standard conditions. The in vivo experiments were performed on 6-week-old BALB/c animals (3 to 6 per group) obtained from Harlan (Corezzana, Italy) and housed and handled according to institutional guidelines and experimental procedures approved by the International Centre for Genetic Engineering and Biotechnology board. Animals were randomly allocated to different treatment groups. Investigator was blinded to allocation when assessing the outcome of tumour challenge experiments.
Cloning of 14F7 and production of rAAV 14F7 mAb heavy and light chain variable regions 48 (GenBank accession numbers AY331718 and AY331717, respectively) were amplified by PCR for cloning into vectors containing the mouse γ1 and κ constant domains, respectively. The whole 14F7 heavy and light chains were then reamplified for cloning into an AAV-2/9 recombinant vector. A recombinant mouse IgG1 antibody was similarly produced as negative control. The light and heavy chains of the antibodies were cloned downstream to the CMV promoter. The 19-amino-acid sequence of the 2A peptide (TLNFDLLKLAGDVESNPGP) from the foot-and-mouth disease virus was cloned upstream to the heavy chain to allow the bicistronic expression of the antibody light and heavy chains. 57 Finally, the furin cleavage site sequence was introduced between the light chain and the 2A peptide to induce the proteolytic cleavage of the 2A peptide residues at the C-terminal portion of the light chain. The rAAV vectors were prepared in the AAV Vector Unit at International Centre for Genetic Engineering and Biotechnology Trieste, as described previously. 58 Briefly, rAAV were generated in HEK-293T cells using a triple-plasmid co-transfection system for packaging. At 12 h after transfection, the medium was replaced by fresh medium and 3 days later the medium was collected and the cells harvested by scraping. After three freeze/thaw cycles in dry ice/ethanol bath and 37°C water bath, cell lysates were fractionated using ammonium sulfate precipitation. The rAAV particles were then purified by CsCl 2 gradient centrifugation in the SW41Ti rotor (Beckman Coulter, Brea, CA, USA) at 288 000 g for 36 h. A total of 12 to 16 fractions of 10 drops each were collected by inserting a G-21 needle below the rAAV band and their refractive index was determined. The six fractions with index closest to 1.3715 (corresponding to a density of 1.40 g cm − 3 ) were dialyzed against phosphate-buffered saline (PBS) at 4°C overnight and stored at − 80°C. The rAAV titres were determined by measuring the copy number of viral genomes in pooled, dialysed gradient fractions. This was achieved by a competitive PCR procedure, using primers and competitors mapping in the CMV promoter region common to all vectors. The purified viral preparations used for this work had particle titres between 3 × 10 13 and 1 × 10 14 viral genome particles per ml.
The in vitro antibody expression and functional activity
To test the expression of the recombinant 14F7, HEK-293T cells were transiently transfected with plasmids pAAV-14F7 and pAAV-ctrl with standard calcium phosphate technique. Cells were transfected in 6-well plates (∼5 × 10 5 cells per well). At 18 h after transfection, medium was discarded and replaced by 2 ml of serum-free medium for 24 h. Medium was collected and analysed by western blot with a horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody (KPL, Gaithersburg, MD, USA). To analyse the binding activity of the recombinant 14F7, supernatants were incubated for 1 h at 4°C with GM3(Neu5Gc)-positive X63-AG8.653 myeloma and L1210 lymphocytic leukemia cells, as well as with GM3 (Neu5Gc)-negative L1210 cmah-kd and CT-26 colon carcinoma cells as negative controls. Cells were washed two times with PBS and stained with a secondary fluorescein-conjugated anti-mouse IgG antibody (Pierce, Waltham, MA, USA). Data were analysed using a FACSCalibur cytometer (Becton Dickinson Immunocytometry, San José, CA, USA).
The in vivo antibody expression and functional activity
For AAV gene transfer, animals were injected with 1 × 10 11 and 3 × 10 12 v.p. of rAAV-14F7 or rAAV-ctrl in the femoral muscle or in the tail vein. The in vivo expression of the 14F7 antibody was measured on ELISA plates coated with purified GM3(Neu5Gc), as previously described. 59 rAAV-mediated targeting of ganglioside GM3(Neu5Gc) GM Piperno et al Briefly, Polysorp immunoplates (Sigma-Aldrich, St Louis, MO, USA) were coated with 1 μg per well of purified GM3(Neu5Gc) ganglioside resuspended in methanol. After drying and washing with PBS, plates were blocked with PBS with 1% bovine serum albumin for 1 h. Serial dilutions of animals' sera were incubated followed by an HRP-conjugated anti-mouse IgG antibody, and binding revealed with TMB substrate (Sigma-Aldrich). Quantification of recombinant 14F7 in animals' sera was performed with ELISA assay, using purified mAb 14F7 as standard.
Binding activity of recombinant 14F7 produced in vivo was performed by flow cytometry on X63-AG8.653 myeloma cells as previously described for the supernatants.
Western blot analysis of sera from rAAV-treated animals was performed as follows. Sera were preincubated on an ELISA plate coated with purified GM3(Neu5Gc). Plate was washed and retained material recovered with SDS and analysed by western blot with an HRP-conjugated anti-mouse IgG antibody (KPL).
To analyse the cytotoxic activity of recombinant 14F7 as expressed in vivo, 5 × 10 4 X63-AG8.653 myeloma cells were incubated with sera for 3 h at 37°C. Cells were washed, stained with propidium iodide and analysed by flow cytometry.
Anti-idiotype immune response
To analyse the presence of antibodies against the idiotype of 14F7 antibody, ELISA plates were coated with a chimeric 14F7 antibody in which mouse constant regions were replaced by the human counterparts. 27 Plates were blocked as indicated before and incubated with sera from animals treated with rAAV-ctrl or rAAV-14F7. As positive control a serum was used obtained from a mouse immunised by gene gun with another recombinant version of 14F7 consisting of the VL-VH single chain Fv covalently linked to mouse γ1 CH3 domain, as described elsewhere for other idiotypes. 60 Reaction was revealed with an HRP-conjugated antimouse IgG antibody (KPL).
Tumour challenge
Tumour challenge experiments were performed essentially as described by Dorvignit et al. (manuscript accepted in Immunobiology). Briefly, BALB/c animals were injected subcutaneously with 2 × 10 5 X63-AG8.653 myeloma cells 4 weeks after rAAV injection. In the second set of experiments, a group of animals were first injected with X63-AG8.653 myeloma cells on day 0 and then treated with i.v. administration of 300 μg per dose of purified 14F7 at days 2, 3, 4 and 5. Tumour appearance and growth were monitored over time and animals killed when moribund.
Statistical analysis
Statistical analysis was carried out using Prism Software (GraphPad Software Inc., La Jolla, CA, USA). For statistical comparison of two groups, unpaired, two-tailed Student's t-test was used. Survival analysis was performed using the Kaplan-Meier product-limit method. The log-rank test was used to compare survival curves. A value of Po0.05 was considered significant.
